Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel OKs 64 More Health Damage Claims for COVID-19 Vaccines
January 16, 2023
- MHLW Panel Urges Better Application of Emergency Approval
January 16, 2023
- MHLW Likely to Give Up Submitting Bill to Lift Bans on Cannabis-Derived Drugs
January 13, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- Japan Panel Recognizes 5 More Deaths Possibly Tied to COVID Vaccines
January 13, 2023
- PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
January 12, 2023
- Japan to Boost Review of Health Damage Claims for COVID-19 Vaccines
January 12, 2023
- 4 Cases of New COVID Variant XBB.1.5 Confirmed in Japan: Govt
January 12, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
- MHLW Eyes April Proposal to Push Generic Industry Shake-Up: Asst. Vice Minister
January 6, 2023
- SCARDA to Fund Vaccine Development by KM Biologics, University of Tokyo for Priority Infectious Diseases
January 6, 2023
- “Pseudonymized Medical Info” to Be Created to Fuel Healthcare Data Use in Filing
January 5, 2023
- Revise Assessment Scheme for Deaths after COVID Shots: MHLW Panel Members
December 28, 2022
- No Add'l Safety Measures for Xocova Needed “at This Time”: MHLW Panel
December 28, 2022
- Japan’s Drug Production Contracts 0.9% to 9.2 Trillion Yen in 2021: MHLW
December 28, 2022
- PMDA Says “Slow Cartagena Review” Is Urban Legend, Set to Dispel Misconception
December 27, 2022
- Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
December 27, 2022
- 1.1 Billion Yen for Revenue Guarantee System for Antibiotics: FY2023 Budget
December 27, 2022
- Funding for Drug Supply Info System Nixed for 2nd Year: FY2023 Budget
December 27, 2022
- Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…